Current gains from immunotherapy in small cell lung cancer (SCLC) Immunotherapy has altered the treatment landscape for SCLC, offering meaningful efficacy where options were once limited. Checkpoint inhibitors that unleash the body’s immune system to attack cancer cells have demonstrated survival benefits in certain patients and disease settings, particularly when used in first-line combinations or…